47results about How to "Meet clinical application requirements" patented technology

An artificial tooth root material with induced osteoplastic bioactivity is prepared through spraying a gradient bioactive layer on the surface of the metallic basic material which has excellent biologic compatibility and combining the bone morphogenetic protein, alkaline fibroblast growth factor, or conversion growth factor onto the surface of said coated layer. Said coated layer contains hydroxyphosphorite nano-powder, bioactive glass nanopowder, alumina nano powder and titanium oxide nano powder. Its advantages are high bioactivity and high adhesion of coated layer.

The invention discloses a creatine jubase detection reagent. The reagent disclosed by the invention consists of a reagent R1 and a reagent R2 according to a volume ratio being 4 to 1, wherein the reagent R1 consists of an imidazole buffer solution, glucose, nano particles, N-acetylcysteine, ethylenediaminetetraacetic acid disodium salt, adenosine diphosphate, coenzyme I, adenine ribonucleotide, pyruvate decarboxylase, 6-phosphogluconic dehydrogenase, hexokinase and sodium dodecyl benzene sulphonate; and the reagent R2 consists of an imidazole buffer solution, phosphocreatine, a preservative and sodium dodecyl benzene sulphonate. Pyruvate decarboxylase and gamma-Fe2O3 nano particles are added into the creatine jubase detection reagent disclosed by the invention, so that interfering substances in a serum sample can be effectively eliminated, metal ions in the serum sample are chelated by matching sodium dodecyl benzene sulphonate and ethylenediaminetetraacetic acid disodium salt, the influence on reaction enzymes is alleviated, and the reagent is a stable, accurate and sensitive detection reagent with high interference resistance.

The invention discloses a method for carrying our surface modification upon biodegradable magnesium and magnesium alloy through iron ion implantation deposition. The method belongs to the technical field of surface treatment. According to the invention, through ion implantation, a composite transition layer doped with iron ions is formed on the surface of magnesium and magnesium alloy. The transition layer is composed of Fe2O3 and MgO, and has a thickness of 20-50nm. An iron film with a thickness of 100-500nm is prepared on the transition layer with an ion-beam-assisted enhanced deposition technology. The transition layer preparation method provided by the invention assists in ensuring good bonding strength between the deposited iron film and the substrate. With the method provided by the invention, corrosion resistance, biocompatibility, and mechanical properties of magnesium and magnesium alloy are improved.

The invention discloses a method for modifying surfaces of biodegradable magnesium and magnesium alloy through titanium ion implantation and deposition, and belongs to the technical field of surface treatment. The method is that mixed oxide transition layers are formed on the magnesium and magnesium alloy surfaces by the ion implantation method, wherein the transition layer is composed of titanium oxide and magnesium oxide and is 3 to 6 microns in thickness; then 2-4 microns titanium films are prepared on the transition layers by the ion beam reinforcing depositing technology. According to the method, the transition layers are prepared to ensure the high combination strength of the titanium depositing film layer and a matrix; the titanium deposition film and the transition layers can improve the corrosion resistance of the magnesium and the magnesium alloy.

The invention relates to the technical field of UREA detection, in particular to a UREA detection reagent. Reagent R1 contains tris buffer, NADPH, and a preservative; reagent R2 contains tris buffer, urease, gluten Acid dehydrogenase, alpha-ketoglutarate, XOD, POD, preservatives. The improved enzymatic urea reagent has superior detection limit and analytical sensitivity, and its own performance is good, which greatly enhances the stability of the reagent and meets the relevant clinical application requirements.

The invention discloses fluorescence immunochromatography test paper for achieving intraoperative judgment of parathyroid tissues through quantitatively detecting a human parathyroid hormone (PTH) and a preparation method of the fluorescence immunochromatography test paper. The test paper capable of detecting the human PTH through a double-antibody sandwich method and a fluorescence immunochromatography; the antibody is prepared by using a specific antigen peptide. The human PTH in a to-be-detected matter can be quickly and accurately detected, so that the fluorescence immunochromatography test paper is simple, convenient and fast to operate, wide in detection range, high in specificity and good in sensitivity.

The invention discloses a double-cavity urethra piezometer tube connecting device which comprises a splitter (1), a single-cavity pipe A (2), a single-cavity pipe B (3), a double-cavity pipe (4) and a plug (5). A primary runner (6) and two secondary runners both communicated with the primary runner (6) are arranged inside the splitter (1), the double-cavity pipe (4) is arranged in the primary runner (6), the side wall of a cavity A (9), close to the secondary runner B (8), of two cavities in the double-cavity pipe (4) is provided with a side hole (10) communicated with the secondary runner B (8), and the plug (5) is arranged in the cavity A (9). The invention further discloses a double-cavity urethra piezometer tube connecting method. According to the double-cavity urethra piezometer tube connecting device and method, the technical method that the side hole and the plug are arranged in the double-cavity pipe is adopted, defects existing in existing connecting methods are ingeniously avoided, and the double-cavity urethra piezometer tube connecting device is simple in process, convenient to manufacture, high in finished product yield, and high in production efficiency and practicality; in addition, the double-cavity urethra piezometer tube connecting device is simple in structure, reliable in product performance and capable of fully meeting clinical application requirements.

The invention relates to a plant polysaccharide cleaning fluid, which is used for intestinal lavage, and takes sodium carboxymethylcellulose as a main ingredient. The plant polysaccharide cleaning fluid comprises the following components in percent by mass: 0.1%-2% of sodium carboxymethylcellulose, 0.7%-1.2% of sodium chloride, 0.01%-0.1% of pH value buffer substances, 0.1%-5% of selectable magnesium chloride, 1%-10% of selectable mannitol, 0.01%-0.1% of selectable phenolphthalein and 0.1%-0.4% of selectable carboxymethyl chitosan, and the balance of water for injection, wherein the pH value of the polysaccharide cleaning fluid ranges from 6.5-7.8. The polysaccharide cleaning fluid is good in cleaning effect, free from adverse effect, and the cleaning fluid is stable and difficult to degrade.

The invention provides a letrozole tablet and a preparation method thereof. The letrozole tablet comprises a tablet core comprising the following components, by weight: 1-4% of letrozole, 20 to 40% ofmicrocrystalline cellulose, 40 to 65% of lactose, 11.5%-16.5% of a disintegrating agent, and 1 to 1.5% of a lubricating agent. On the basis of the total weight of the tablet core, the lubricating agent comprises 0.3%-0.5% of magnesium stearate and 0.7%-1.0% of superfine silica powder; and the disintegrating agent comprises 3%-7% of sodium carboxymethyl starch and 8.5%-9.5% of corn starch. After controlling of the use amounts of the corn starch and the sodium carboxymethyl starch, on the one hand, the disintegration time of the letrozole tablet is regulated and controlled;and on the other hand, the mixing uniformity of the superfine silica powder in the mixing and tabletting processes is ensured and the demixing phenomenon is avoided. The dosage ratio of the superfine silica powder, the lactose and the corn starch is strictly controlled, so that the mixing uniformity of the materials and the dissolution rate of the letrozole are guaranteed. The clinical application requirements are met.

The invention provides a letrozole tablet and a preparation method thereof. The letrozole tablet comprises a tablet core comprising the following components, by weight: 1-4% of letrozole, 20 to 40% ofmicrocrystalline cellulose, 40 to 65% of lactose, 11.5%-16.5% of a disintegrating agent, and 1 to 1.5% of a lubricating agent. On the basis of the total weight of the tablet core, the lubricating agent comprises 0.3%-0.5% of magnesium stearate and 0.7%-1.0% of superfine silica powder; and the disintegrating agent comprises 3%-7% of sodium carboxymethyl starch and 8.5%-9.5% of corn starch. After controlling of the use amounts of the corn starch and the sodium carboxymethyl starch, on the one hand, the disintegration time of the letrozole tablet is regulated and controlled;and on the other hand, the mixing uniformity of the superfine silica powder in the mixing and tabletting processes is ensured and the demixing phenomenon is avoided. The dosage ratio of the superfine silica powder, the lactose and the corn starch is strictly controlled, so that the mixing uniformity of the materials and the dissolution rate of the letrozole are guaranteed. The clinical application requirements are met.

An intracranial pressure monitoring instrument based on ultrasonic wave acoustoelastic effect comprises a computer, an ultrasonic wave transmitting drive module, an ultrasonic wave transmitter, an ultrasonic wave receiver and a receiving signal circuit module, wherein the ultrasonic wave transmitting drive module is used for generating initial high-frequency signals, the ultrasonic wave transmitter is connected with the ultrasonic wave transmitting drive module and converts the initial high-frequency signals output by the ultrasonic wave transmitting drive module into elastic mechanical waves transmitting to a cranial cavity, the ultrasonic wave receiver is used for receiving the elastic mechanical waves penetrating the cranial cavity and converting the received elastic mechanical waves into tail-end high-frequency signals, the receiving signal circuit module is connected with the ultrasonic wave receiver and used for performing frequency discrimination and phase locking to the tail-end high-frequency signals and outputting the phase, with the same frequency as the initial high-frequency signals, of the tail-end high-frequency signals to the computer, and the computer is connected with the ultrasonic wave transmitting drive module and the receiving signal circuit module and used for demodulating the tail-end high-frequency signals and calculating intracranial pressure. By the intracranial pressure monitoring instrument, noninvasive monitoring of intracranial pressure of patients is achieved, measuring data is accurate, the clinical application requirements can be satisfied, and long-term online monitoring is achieved.

The invention provides an adhesive for the department of orthopaedics and a preparation method of the adhesive. The adhesive comprises the following components: silicate, phosphate, sodium alginate, magnesium oxide, calcium carbonate, kaolin, propylene glycol, glycerin, a retarder and deionized water. The preparation method comprises the following steps: weighing all the raw materials in parts by weight; performing ball-milling on silicate, phosphate, magnesium oxide, calcium carbonate and kaolin into powders, and uniformly mixing the five powders to obtain a mixture; sequentially adding sodium alginate, propylene glycol, glycerin and the retarder in the deionized water, uniformly stirring to obtain a settled solution, slowly adding the mixture in the settled solution under the condition of continuously stirring, and performing ultrasound at the room temperature to obtain the adhesive. The adhesive for the department of orthopaedics, prepared by the preparation method, is high in comprehensive performance, finally sets for about 60 minutes, has the compressive strength of 54.6-58.3 MPa, can meet the clinical application requirement, and is suitable for the treatment of osteoporosis and the fracture fixation and treatment in the department of orthopaedics and the spine surgery.

The invention discloses a method for rapidly identifying human parathyroid glands. The method is realized by using parathyroid hormone (PTH) fluorescence immunochromatography test paper to determine the content of PTH in liquid to be detected; the test paper is used for detecting human PTH by using a double-antibody sandwich method and a fluorescence immunochromatography; the antibodies are prepared by using specific antigenic epitope peptide. The method can be used for accurately detecting the human PTH in a matter to be detected, and is simple and convenient to operate, wide in detection range, high in specificity and good in sensitivity.

The invention discloses a high-strength calcium phosphate composite nano material bone cement which is composed of a solid-phase powder and a liquid phase, wherein the solid-phase powder is composed of the following raw materials in parts by weight: 5-20 parts of tricalcium phosphate, 30-70 parts of hydroxyapatite and 1-10 parts of gamma-aluminum oxide nanotube; the liquid phase is a water solution containing 1-10 wt% of citric acid, 0-6 wt% of chitosan and 5-15 wt% of glucose; and before use, the solid-phase powder and liquid phase are blended according to the liquid phase:solid phase ratio of 1ml:(0.3-0.8)g. The invention also discloses a preparation method of the bone cement. The bone cement material has the advantages of favorable comprehensive properties and high compression strength, and is convenient to operate; the maximum compression strength can reach 120 MPa, which is much higher than that of the existing calcium-phosphate-base bone cement; and the bone cement material with favorable injectability can satisfy the clinical application requirements, and is suitable for restoring hard tissue bone defects, treating osteoporosis, and fixing and treating fractures.

The invention relates to a novel plant polysaccharide cleaning fluid which is used for cleaning intestinal tracts and uses oxycellulose as a main ingredient. The novel plant polysaccharide cleaning fluid comprises the following components in percentage by weight: 0.1-2% of oxycellulose, 0.8-1.0% of sodium chloride, 0.01-0.1% of pH value buffering substances, optional components (0.1-5% of magnesium chloride, 1-10% of mannitol, 0.01-0.1% of phenolphthalein and 0.1-0.4% of carboxymethyl chitosan), and the balance of water for injection. The pH value range of the novel plant polysaccharide cleaning fluid is 6.5-7.8. The novel plant polysaccharide cleaning fluid provided by the invention has a good cleaning effect and zero bad influences.

The invention relates to a plant polysaccharide cleaning solution mainly composed of sodium carboxymethyl cellulose for intestinal cleaning, which comprises the following components: sodium carboxymethyl cellulose with a mass percentage of 0.1% to 2% , 0.7% to 1.2% by mass of sodium chloride, 0.01% to 0.1% by mass of pH value buffer substances and optional magnesium chloride, mannitol, phenolphthalein and carboxymethyl chitosan, the rest The amount is water for injection, wherein the mass percentage of magnesium chloride is 0.1% to 5%, the mass percentage of mannitol is 1% to 10%, the mass percentage of phenolphthalein is 0.01% to 0.1%, and the mass percentage of carboxymethyl chitosan The percentage content is 0.1%-0.4%, and the pH range of the plant polysaccharide cleaning solution is 6.5-7.8. The plant polysaccharide cleaning solution provided by the invention has good cleaning effect, no adverse reaction, and the cleaning solution is stable and difficult to degrade.

The invention discloses a preparation method and application of a biomedical degradable zinc-alloy capillary tube. The preparation method comprises the following steps: subjecting cast zinc alloy to heat treatment and machining so as to form a cylinder and carrying out hot extrusion on the cylinder to obtain an extruded bar; processing the extruded bar to form an extruded tube blank and carrying out hot extrusion on the extruded tube blank to obtain an intermediate tube with an external diameter Phi of 3 to 8 mm; carrying out a plurality of passes of room-temperature rolling until the capillary tube blank has an external diameter Phi of 2 to 3 mm and wall thickness of 0.10 to 0.20 mm; and carrying out room-temperature drawing to eventually obtain a capillary tube with a diameter Phi of 1 to 3 mm and carrying out annealing treatment so as to obtain the capillary tube for cutting stents and with yield strength Rp0.2 of 250 to 450 MPa, tensile strength of 280 to 460 Pa and elongation percentage of 11 to 72%. The biomedical degradable zinc-alloy capillary tube prepared in the invention has appropriate strength and excellent elongation percentage and is applicable to preparation of intravascular stents, nerve conduits and other medical implant products.

The invention discloses a method for surface modification of biodegradable iron and iron alloy by zinc ion implantation, which belongs to the technical field of surface treatment. In the present invention, a modified layer doped with zinc is formed on the surface of iron and iron alloy by zinc ion implantation. In the surface modified layer, a mixture phase of iron-zinc second phase, iron oxide and zinc oxide is formed, with a thickness of 50 ~100nm, the implanted element zinc shows a Gaussian distribution. The zinc surface modification layer prepared by the invention has good bonding strength with the substrate, improves the corrosion rate of iron and iron alloy, and has good biocompatibility at the same time.

The invention relates to the field of biochemical medicines, in particular to a stabilizer for clinical lentivirus and a use method of the stabilizer. The stabilizer for clinical lentivirus comprises10-20 g / ml of sucrose, 40-100 mg / L of tocopherol, 10-20g / ml of human albumin, and the balance of 0.01 mol / L of a PBS buffer with the pH value being 7.4, and is obtained by filtering with a 0.22-micronfilter. The use method of the stabilizer for clinical lentivirus comprises the following steps: gently and uniformly mixing a clinical lentivirus suspension with the stabilizer for clinical lentivirus at a volume ratio of 9:1; sub-packaging; and storing the sub-packaged clinical lentivirus suspension in an environment at -80 DEG C. After verification, the clinical lentivirus using the stabilizerprovided by the invention has no drop in titer after being stored at -80 DEG C for 6 months, has no significant drop in titer after one freeze-thaw cycle, and has a titer loss of only 10% after threefreeze-thaw cycles, thereby satisfying storage requirements in production, transportation and use processes of lentivirus. The stabilizer provided by the invention has simple components and few use steps, does not need to use additional instrument and equipment, is easy to control quality and meets requirements of clinical application.